Congratulations on the positive phase I clinical results of Raymon Pharma's first Chinese eye drops for the treatment of wAMD
Recently, Raymon Pharma announced that the clinical trial of self-developed RA1115-B1 eye drops for the treatment of neovascular (wet) age-related macular degeneration (wAMD) was launched in China. The Phase I clinical trial at Peking Union Medical College Hospital of the Academy of Medical Sciences, chaired by the principal investigators Professor Youxin Chen and Associate Professor Rui Che, has been completed with positive results. In the research and development of RA1115-B1 eye drops, Shanghai Medicilon Inc. (Medicilon) provided pharmaceutical research services such as raw material drug production, raw material drug process development, and preparation prescription process development to accelerate the R&D process. The first eye drops for the treatment of wAMD in China The therapeutic potential of RA1115-B1 is initially shown Wet age-related macular degeneration is a vision killer for middle-aged and elderly people. Among the irreversible blinding eye diseases...